Assessment of Antitachycardia Pacing in Primary Prevention Patients: The APPRAISE ATP Randomized Clinical Trial.

ABSTRACT:

Importance

The emergence of novel programming guidelines that reduce premature and inappropriate therapies along with the availability of new implantable cardioverter-defibrillator (ICD) technologies lacking traditional endocardial antitachycardia pacing (ATP) capabilities requires the reevaluation of ATP as a first strategy in terminating fast ventricular tachycardias (VTs) in primary prevention ICD recipients.

Objective

To assess the role of ATP in terminating fast VTs in primary prevention ICD recipients with contemporary programming.

Design, setting, and participants

This global, prospective, double-blind, randomized clinical trial had an equivalence design with a relative margin of 35%. Superiority tests were performed at interim analyses and the final analysis i

SUBMITTER: Schuger C 

PROVIDER: S-EPMC11581509 | biostudies-literature | 2024 Nov

REPOSITORIES: biostudies-literature